Method of prevention of bleeding caused by the application of antiagregants, experiment stage

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to experimental surgery, and can be used to prevent bleeding when applying double antiplatelet therapy before surgery. To this end, a solution containing fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml is given to a rabbit-male chinchilla one hour before the operation. In this case, the dose of fibrin monomer is 0.25 mg/kg.

EFFECT: method is highly effective, since it not only reduces the amount of blood loss, but also is safe when applied.

1 cl, 2 dwg

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %.

EFFECT: method enables recovering the spinal cord function sufficiently completely in the distal direction from the injury region, providing the favourable conditions for the adequate neuroglial growth with recipient's long neuron penetration from the intact proximal portion of the spinal cord into the distal one to ensure its conductive function, reducing the cicatrisation within the spinal injury, and eliminating the cerebral tissue oedema.

3 cl, 8 ex

FIELD: medicine.

SUBSTANCE: to a laboratory animal - rat - carried out is a unilateral nephrectomy, denervation and delymphatisation of the second kidney. After that the renal artery and vein are clamped for 40-60 minutes. After carrying out the surgical operation the triple immunisation of the laboratory animal with a kidney antigen, obtained from the removed kidney is carried out by an adjuvant method. 5 weeks before the surgical operation sampling of bone marrow cells from the laboratory animal is carried out, a culture of multipotent mesenchymal stromal cells is obtained from them in vitro. The denervation and delymphatisation of the remaining kidney is carried out by the removal of the adventitia and cellular tissue, wrapping the ureter, renal artery and vein, in the area of the hiluses renalis at a distance of 7-10 mm and decapsulation of the kidney in the area of its medial edge 7-10 mm wide, extension from one pole of the kidney to the other with the capture of the area of its hiluses. To obtain the kidney antigen the safe kidney is applied and the content of protein in it is brought to 70 mg/ml. On 35-40 day after carrying out the surgical operation the obtained culture of the multipotent mesenchymal stromal cells is introduced to the same animal intravenously in a dose of 1.5-3.0 mln cells in 1 ml of physiological solution.

EFFECT: method makes it possible to create an adequate, available for execution model of chronic rejection in autologous kidneys in small laboratory animals with an accelerated development of visualised destructive post-transplantation processes.

1 ex, 1 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: chemical burn is simulated in laboratory rats. From the 5th day following the simulation, therapeutic agents are administered abdominally. That involves using cefotaxime 100 mg/kg for 7 days. Prednisolone is administered in a dose of 1 mg/kg for 3 days. 3% Xymedone is administered in a dose of 30 mg/kg once a day for 40 days.

EFFECT: effective treatment of burns of the oesophagus and stomach by fast recovery of the thickness of a muscular layer of the mucous tunic and prevention of cicatrisation.

1 tbl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment tests, namely to production tests of joint implants with a metal friction pair the state of which is assessed in the course of testing with using electric (electrically resistive) diagnostic techniques. The diagnostic technique for joint implants with the metal friction pair consisting in the fact that the implant is mounted in a test bench loaded with axial force; a lubricant layer is formed between surfaces of the implant components, and the physical characteristics of the surface layer of the components in the friction zone are measured. Small AC current is passed through the friction zone of the implant; a temporary function of complex impedance of the implant tribocoupling is recorded; it uses its active and reactive component parameters to show an actual thickness of the lubricant layer and a lubricant type prevailing in the tribocoupling and a friction regimen. The actual technical condition of the joint implant tribocoupling is assessed by a ratio of the time intervals when the active part of the complex impedance is more than the reactive part to the total measurement time.

EFFECT: invention provides shortening the test time, assessing the real time of the contact of the friction surfaces, increasing the produced valid signal power and noise stability, in obtaining the objective initial diagnostic information from the friction zone in order to predict a durability of the joint implant with the metal friction pair.

5 dwg

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: limb ischemia is simulated in a male Wistar rat anaesthetised with chloral hydrate in a dose of 250-300 mg/kg by the surgical removal of femoral, popliteal arteries and the front shin artery. That is followed by introducing a prepared mononuclear fraction of the autologous bone marrow in a dose of 4×106 cells in an amount of 200 mcl. The above is introduced into the ischemic limb from two points in an amount of 100 mcl each. One point is found directly under the femoral arch paravasally within the anatomical position of collaterals of the inner iliac artery and its branches. The other point is located in the calf muscle on an anteriolateral surface of the midleg.

EFFECT: more effective experimental treatment ensured by stimulating the collateral blood flow in the ischemic limb and improving the arterial blood flow from the proximal to distal parts of the limb.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method consists in a single administration of a mixture consisting of a rat's homogenised myocardial tissue - 25%, egg albumin - 25% and Freund's adjuvant - 50%, into old male rats. The method involves administering in an amount of 0.3 ml into 5 injection points: intraperitoneally, into inguinal and axillary regions from the left and right.

EFFECT: being easy to reproduce and cost efficient, the method is effective for creating a model aiming at a possibility of studying the pathogenesis, preventing and treating cardiopathy.

2 dwg, 1 tbl, 1 ex

Phantom test // 2555129

FIELD: medicine.

SUBSTANCE: phantom test consists of two parts being a single whole. One part has a constant longitudinal height, while the other part has a continuously varying longitudinal height forming a wedge. On the side of the wedge, there are calibrated notches.

EFFECT: more accurate determination of the bone mineral density by X-ray images formed with the help of a general-application X-ray machine, and simplifying the design.

7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, pathologic physiology, and concerns simulating acute pancreatitis. To this effect, the method involves ligaturing the main truck of the excretory duct of the pancreas, administering an aggressive solution into the pancreatic duct system, and removing the ligature. The aggressive solution represents 1% chenodeoxycholic acid with 5% sodium hydrogen carbonate in an equal proportion in an amount of 0.3-0.5 ml at 10-15 mg/kg of the animal's body weight.

EFFECT: method enables developing a model of acute fatty, hemorrhagic or mixed pancreatitis in the animal that makes it applicable for improving the known methods for conservative and radical methods of treating.

15 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and concerns simulation in vivo of cortical cataract. That is ensured by a double-side surgical sympathectomy by excising a superior cervical sympathetic ganglion.

EFFECT: by simplicity and effectiveness of modulation, the method provides forming the cortical lens-form opacity, which is morphologically and immunohistochemically identical to lens cell changes in age-related lens opacity in a human.

6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.

EFFECT: material is degradable in the body and promotes osteal wound healing.

7 cl, 4 tbl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.

1 ex, 2 dwg

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.

EFFECT: group of inventions relates to improvement of octreotide bioavailability.

100 cl, 39 ex, 10 dwg, 45 tbl

FIELD: medicine.

SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.

EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.

EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.

3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula

.

The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: phenazepamum 1.0 mg is prescribed per os to patient on the eve of planned operation; then, in pre-narcosis room after catheterisation of peripheral vein suprastinum in dose 0.3 mg/kg of patient's body weight and atropine in dose 0.01 mg/kg of patient's body weight are introduced intramuscularly 30 minutes before operation. After that, solution of dexmedetomidine with concentration 4.0 mkg/ml in dose 1.0 mcg/kg of patient's body weight is introduced by intravenous infusion by syringe-batcher for 10 min.

EFFECT: method ensures optimal level of sedation and stability of haemodynamics indexes at the background of reduction of patient's psycho emotional stress and preservation of their contact with medical staff.

2 ex

Up!